China Hyaluronidase Market Size, Share, Growth Report 2030

China Hyaluronidase Market

China Hyaluronidase Market By Type (Animal-Derived Hyaluronidase, Synthetic Hyaluronidase), By Application (Chemotherapy, Dermatology, Ophthalmology, Plastic Surgery, and Others), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2023 – 2030

Category: Chemical & Materials Report Format : PDF Pages: 230 Report Code: ZMR-5712 Published Date: May-2023 Status : Published
Market Size in 2022 Market Forecast in 2030 CAGR (in %) Base Year
USD 44.80 million USD 176.60 million 18.56% 2022

Industry Perspective:

The China hyaluronidase market size is set for rapid growth over the forecast period. In terms of revenue, the Hyaluronidase market in China accounted for USD 44.8 Million in 2022 and is expected to reach USD 176.6 Million by 2030, growing at a CAGR of 18.56% during the forecast period.

Global China Hyaluronidase Market SizeRequest Free Sample

The market report offers remarkable insights into the essential drivers, opportunities, constraints, and challenges impacting the global China hyaluronidase industry.

China Hyaluronidase Market: Overview

The demand for Chinese hyaluronic acid-based dermal fillers is anticipated to rise at the highest growth rate during the forecast period. Due to its large market size, expanding population, and sedentary lifestyle, China's market has both medium to long-term potential.

In China, the overall sales of hyaluronic acid raw materials broke the record at about 430 metric tons in 2018, accounting for more than 80% of the worldwide sales volume. The demand for hyaluronic acid, which is widely used in treatments to maintain moisture in the skin, is also continuously growing as the cosmetic surgery industry in China is booming.

One fact behind China's escalating cosmetic surgery industry is the growth of the middle class in Chinese society. The rise in the buying power of more than 350 million Chinese lifted the level of living standards of citizens to allow them to aspire to other extravagances and standards of life. The procedure is no longer limited to enhancing the appearance of people with disfigured faces arising from incidents and injuries; for naturally good-looking people, it is now like having the "icing on the cake".

In contrast to other dermal fillers, sodium hyaluronic acid filler (HA filler) is the most mature commodity in China. Such a product has a higher rate in the beauty field. Moreover, hyaluronic acid is also one of the compositions in the human body and thus it also has good biocompatibility. HA filler is also generally used in the field of medicine and medical devices; it has been widely known for its protection and efficacy.

In recent decades, so many more international companies are preparing to import HA filler into the Chinese market, with many foreign companies already successfully opening their markets and welcoming clinics and beauty salons. For current HA fillers, comb purification or biological fermentation filtration is their key raw material, they are colorless and cross-linked. The HA filler market is showing a dramatic increase and in the following decades, there will be great market rivalry.

Key Insights

  • As per the analysis shared by our research analyst, the global China hyaluronidase market is expected to grow annually at a promising CAGR of around 6.6% during the forecast period 2023-2030.
  • In terms of revenue, the global China hyaluronidase market size was valued at around USD 46.6 billion in 2022 and is expected to reach USD 74.8 billion by 2030.
  • The China hyaluronidase market is projected to boost owing to the increasing demand for hyaluronidase in cosmetic procedures
  • Based on type, the animal-based hyaluronidase segment held the dominating market share in 2022.
  • Based on application, the dermatology segment held the largest market share in 2022.

China Hyaluronidase Market: Drivers

Increase in the use of hyaluronidase in various cosmetic procedures drive the growth of the market

The drivers of the China hyaluronidase market include the increasing demand for hyaluronidase in cosmetic procedures. The use of hyaluronidase is particularly prevalent in the removal of dermal fillers, which has become an increasingly popular cosmetic treatment. Additionally, the growing prevalence of hyaluronidase in medical settings such as ophthalmology and plastic surgery is driving market growth. Furthermore, technological advancements in the production and application of hyaluronidase are also contributing to the growth of the market.

China Hyaluronidase Market: Opportunities

Rising trend of non-invasive medical procedures might create ample opportunities for the industry

The opportunities in the China hyaluronidase industry include the potential for expanded use of the enzyme in medical applications beyond the current scope. There is potential for hyaluronidase to be used in the treatment of various medical conditions, including cancer and inflammation.

Additionally, there is an opportunity for increased research and development into new applications for hyaluronidase, which could further expand the market. The growing demand for non-invasive cosmetic procedures in China presents another opportunity for market growth, as hyaluronidase can be used to quickly and safely remove dermal fillers.

China Hyaluronidase Market: Restraints

Extortionate cost of enzymes and lack of awareness among people might hinder the growth to some extent

The China hyaluronidase market faces several restraints, including the lack of standardized regulation of the enzyme's use in cosmetic procedures. This can lead to misuse and potential harm to patients. Additionally, there is a lack of awareness among patients and healthcare providers regarding the benefits and risks of hyaluronidase. The high cost of the enzyme and potential side effects, including allergic reactions, also present as a restraint for market growth.

China Hyaluronidase Market: Challenges

Presence of alternatives might act as a challenge to the growth of the market

Another challenge for the China hyaluronidase industry is the presence of alternative treatments for the removal of dermal fillers. These alternatives include manual massage and injection of saline solution. Additionally, the ongoing COVID-19 pandemic has affected the healthcare industry in China, potentially leading to delays in procedures and a decrease in demand for hyaluronidase. Furthermore, the long-term effects of repeated use of hyaluronidase in cosmetic procedures are not yet fully understood, which could also hinder market growth.

China Hyaluronidase Market: Segmentation

The China hyaluronidase market is segmented based on type, application, and region

Based on type, the market is bifurcated into Animal-Derived Hyaluronidase and Synthetic Hyaluronidase. The animal-derived hyaluronidase segment held the largest market share in 2022 and is further projected to grow exponentially during the forecast period. The animal-derived hyaluronidase segment of the market has been growing steadily in recent years. This is due to the established use of animal-derived hyaluronidase in medical settings and its efficacy in treating a range of conditions.

In addition, animal-derived hyaluronidase has a longer shelf life and is more stable than synthetic hyaluronidase, which makes it a preferred choice for certain applications. The growing demand for aesthetic treatments has also contributed to the growth of the animal-derived hyaluronidase market, as it is used to dissolve dermal fillers. Furthermore, the increasing prevalence of chronic diseases such as cancer and the need for rapid drug delivery has created new opportunities for the use of animal-derived hyaluronidase. With ongoing research and development, this segment of the market is expected to continue to grow in the future.

Based on application, the market is segmented into Chemotherapy, Dermatology, Ophthalmology, Plastic Surgery, and others. The Dermatology segment held the largest market share in 2022 and is further projected to grow exponentially during the forecast period. The dermatology segment of the China hyaluronidase market has been experiencing significant growth in recent years. This is due to the increasing demand for aesthetic treatments and the use of hyaluronidase to dissolve dermal fillers. Hyaluronidase is used to reverse the effects of hyaluronic acid-based fillers and to treat complications such as overfilling, nodules, and bumps.

The procedure is minimally invasive and provides immediate results, making it a popular choice for patients. Furthermore, the high prevalence of skin conditions such as acne, eczema, and psoriasis has also contributed to the growth of this segment of the market. With ongoing technological advancements and increasing awareness about the benefits of hyaluronidase, the dermatology segment of the China hyaluronidase market is expected to continue to grow in the future.

Recent Developments

  • In 2019, Bloomage Biotechnology announced that it had signed a strategic collaboration agreement with Haohai Biological Technology to jointly develop and commercialize hyaluronic acid and hyaluronidase products for the Chinese market. The collaboration aims to leverage the expertise and resources of both companies to bring innovative solutions to the market.
  • In 2021, Shandong Freda Biotechnology launched a new hyaluronidase product, which is derived from Streptococcus zooepidemicus. The product is marketed as a sterile freeze-dried powder for injection and is indicated for the treatment of hyaluronic acid-based filler complications and the improvement of skin elasticity and moisture.

China Hyaluronidase Market: Report Scope

Report Attributes Report Details
Report Name China Hyaluronidase Market Research Report
Market Size in 2022 USD 44.8 Million
Market Forecast in 2030 USD 176.6 Million
Growth Rate CAGR of 18.56%
Number of Pages 230
Key Companies Covered Bloomage BioTechnology Corporation Limited, Q-Med AB, IBSA Farmaceutici Italia Srl, Guangdong Techpool Bio-Pharma Co. Ltd., Shandong Runxin Biotechnology Co., Ltd., China Resources Double-Crane Pharmaceutical Co., Ltd., Jiangsu Wanbang Biopharmaceuticals Co., Ltd., Lanzhou Institute of Biological Products Co. Ltd., Shanghai Sunflower Group Co., Ltd., Hangzhou Huadong Medicine Group Sanxing Pharmaceutical Co., Ltd., LifeTech Scientific Corporation, Shanghai Jingfeng Pharmaceutical Co., Ltd., Sichuan Kelun Pharmaceutical Co., Ltd., Hebei Changshan Biochemical Pharmaceutical Co., Ltd., Changzhou Institute of Pharmaceutical Research Co. Ltd., Henan Lingrui Pharmaceutical Co., Ltd., Shenzhen Techdow Pharmaceutical Co., Ltd., Wuhan Wuyao Pharmaceutical Co., Ltd., Zhejiang Haizheng Pharmaceuticals Co. Ltd., and Tonghua Dongbao Pharmaceutical Co., Ltd.
Segments Covered By Type, By Application, and By Region
Regions Covered North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA)
Base Year 2022
Historical Year 2017 to 2021
Forecast Year 2023 - 2030
Customization Scope Avail customized purchase options to meet your exact research needs. Request For Customization

China Hyaluronidase Market: Regional Analysis

The Chinese economy is very much a Research & Development (R&D) economy, which is the key driver of China's business growth. Rising disposable personal income and affecting average income combined with changing consumer preferences in the Chinese population are some of the major factors driving the growth of the business. In addition, the significant presence of the middle-aged population is also among the major factors contributing to the growth of the Chinese market.

In terms of revenue and consumption value, China is the second-largest cosmetics market in the world after the United States. It is also one of the fastest-growing and most promising business sectors in China. The beauty and personal care market is facing a booming demand for higher quality, luxury, powerful brand items, owing to increasing disposable income, urbanization, and social media influence. China's retail trade in cosmetics held almost 300 billion yuan in 2019 and is further projected to exceed nearly 400 billion yuan by 2023.

Another dynamic that drives a high number of Chinese people to use cosmetic surgery is the power of Korean culture. This is because of the Korean Wave's rising success through Korean dramas and TV programs that have become a sensation in China. Since cosmetic surgery in Korea is widespread, the Chinese people have been strongly influenced by television characters with their jaw in V line, unbridled eyes, and notable cheekbones. All these factors are expected to drive the hyaluronidase market in China

China Hyaluronidase Market: Competitive Landscape

Some of the players of Hyaluronidase in China include:

  • Bloomage BioTechnology Corporation Limited
  • Q-Med AB
  • IBSA Farmaceutici Italia Srl
  • Guangdong Techpool Bio-Pharma Co. Ltd.
  • Shandong Runxin Biotechnology Co. Ltd.
  • China Resources Double-Crane Pharmaceutical Co. Ltd.
  • Jiangsu Wanbang Biopharmaceuticals Co. Ltd.
  • Lanzhou Institute of Biological Products Co. Ltd.
  • Shanghai Sunflower Group Co. Ltd.
  • Hangzhou Huadong Medicine Group Sanxing Pharmaceutical Co. Ltd.
  • LifeTech Scientific Corporation
  • Shanghai Jingfeng Pharmaceutical Co. Ltd.
  • Sichuan Kelun Pharmaceutical Co. Ltd.
  • Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
  • Changzhou Institute of Pharmaceutical Research Co. Ltd.
  • Henan Lingrui Pharmaceutical Co. Ltd.
  • Shenzhen Techdow Pharmaceutical Co. Ltd.
  • Wuhan Wuyao Pharmaceutical Co. Ltd.
  • Zhejiang Haizheng Pharmaceuticals Co. Ltd.
  • Tonghua Dongbao Pharmaceutical Co. Ltd.

The China hyaluronidase market report is segmented as follows:

By Type

  • Animal-Derived Hyaluronidase
  • Synthetic Hyaluronidase

By Application

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France 
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

Methodology

FrequentlyAsked Questions

Hyaluronidase is an enzyme that breaks down hyaluronic acid, a substance found in the body's tissues, to facilitate the spread of other injected drugs. It is used in medicine to improve the absorption and distribution of drugs and in cosmetic procedures to dissolve unwanted fillers and improve their appearance.

The China hyaluronidase market is predicted to increase at a CAGR of 18.56% during the forecast period.

The China hyaluronidase market was worth around USD 44.8 Million in 2022 and is expected to reach USD 176.6 million by 2030.

The China hyaluronidase market is being driven by several factors, including the increasing demand for hyaluronidase in cosmetic procedures, particularly for the removal of dermal fillers, and the growing prevalence of hyaluronidase in medical settings, such as ophthalmology and plastic surgery. Other drivers include technological advancements and increasing investments in research and development.

Some of the major companies operating in the China hyaluronidase market include Bloomage BioTechnology Corporation Limited, Q-Med AB, IBSA Farmaceutici Italia Srl, Guangdong Techpool Bio-Pharma Co. Ltd., Shandong Runxin Biotechnology Co., Ltd., China Resources Double-Crane Pharmaceutical Co., Ltd., Jiangsu Wanbang Biopharmaceuticals Co., Ltd., Lanzhou Institute of Biological Products Co. Ltd., Shanghai Sunflower Group Co., Ltd., Hangzhou Huadong Medicine Group Sanxing Pharmaceutical Co., Ltd., LifeTech Scientific Corporation, Shanghai Jingfeng Pharmaceutical Co., Ltd., Sichuan Kelun Pharmaceutical Co., Ltd., Hebei Changshan Biochemical Pharmaceutical Co., Ltd., Changzhou Institute of Pharmaceutical Research Co. Ltd., Henan Lingrui Pharmaceutical Co., Ltd., Shenzhen Techdow Pharmaceutical Co., Ltd., Wuhan Wuyao Pharmaceutical Co., Ltd., Zhejiang Haizheng Pharmaceuticals Co. Ltd., and Tonghua Dongbao Pharmaceutical Co., Ltd.

Choose License Type

  • zion payment modes

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed